Astrazeneca (AZN) said Saturday the full results from the Phase III trial showed Tezspire or tezepelumab, an asthma treatment jointly developed with Amgen (AMGN), led to significant reductions in nasal polyp severity, surgery requirements, and systemic corticosteroid use for patients with chronic rhinosinusitis with nasal polyps, compared with placebo.
At week 52, Tezspire improved the co-primary endpoints, reducing Nasal Polyp Score by -2.065 and nasal congestion by -1.028 compared with placebo, with benefits observed as early as weeks four and two respectively.
These findings were published in the New England Journal of Medicine and presented at the American Academy of Allergy Asthma & Immunology and World Allergy Organization Joint Congress in San Diego, California on Saturday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。